Abstract: The present invention provides a crystalline form of HPPH (2-((1?-n-hexyloxy)ethyl)-2-divinyl-pyropheophorbide-a): The crystalline form can be characterized by an X-ray powder diffraction (XRD) pattern and differential scanning calorimeter (DSC) pattern. The present invention also provides a method for preparing the crystalline form of HPPH.

Abstract: The hardness of zinc sulfide is increased by adding selective elements within a specified range to the crystal lattice of the zinc sulfide. The increased hardness over conventional zinc sulfide does not substantially compromise the optical properties of the zinc sulfide. The zinc sulfide may be used as a protective coating for windows and domes.

Abstract: Provided are derivatives substituted by urea associated with 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine-2-amino of formula (I), wherein these compounds may selectively regulate or inhibit an information transmission process controlled by natural or variant tyrosine kinase. Also provided are preparation methods and uses of the compounds.

Abstract: A device comprising an electrostatic discharge protection structure (8), an ion sensitive field effect transistor (ISFET) having a floating gate (5,6,7,9,10), and a sensing layer (12) located above the floating gate. The device is configured such that the electrical impedance from the sensing layer to the electrostatic discharge protection structure is less than the electrical impedance from the sensing layer to the floating gate. The device can be fabricated in a standard CMOS process.

Abstract: Disclosed are a cyanine dye compound and a preparation method therefor, and a dual-function agent for photodynamic therapy and a preparation method therefor. The provided cyanine dye compound is connected to multiple markers, which improves the accuracy of combination of dye and tumor cells, effectively reduces the background value, and avoids excessive residues in the liver. The provided cyanine dye compound is conjugated with the photosensitizer at 2?? position, so that tumor highly absorbs the conjugates.

Abstract: A general purpose DC-AC inverter in an electrified automobile system provides DC-AC inverter control based on different types of the motors. The DC-AC converter is configured to convert a voltage from a primary battery system of the EV to different voltage/current waveforms. One controller controls different types of motors without changing the firmware. Sensorless control is also achieved based on the same firmware.

Abstract: The present invention relates to a method for preparing highly pure doxorubicin. The method comprises the following steps: (1) chromatographing a prepurified doxorubicin solution by using macroporous resin, pre-washing the chromatographed system by using an acidic low concentration aqueous organic solvent, and performing elution by using an acidic high concentration aqueous organic solvent; (2) performing chromatographic separation on eluted components by using a preparative column, so that a highly pure doxorubicin component can be obtained, and the doxorubicin can, if needed, be separated from the aqueous solution by using conventional concentration and crystallization methods in the prior art. The present invention has the advantages such as simplicity, high yield, low cost, and less environmental pollution. The content of the prepared doxorubicin is greater than 99.5%, the content of each impurity is controlled to be lower than 0.10%, and the USP and EP standards are met.

Abstract: The present invention relates to a process of a chemically synthetic drug, and in particular, to a new intermediate of a heparin pentasaccharide and a preparation method thereof. The process has high reaction efficiency, and an easy reaction operation. The reaction intermediate is easy to be purified, and is appropriate for an industrialization production.

Abstract: Disclosed is a process for chemically synthesizing a pharmaceutical intermediate, in particular to a novel intermediate and novel process for synthesizing an anticoagulant drug fondaparinux sodium intermediate—full protection heparin pentasaccharide. The process has a high reaction efficiency and a simple reaction operation, and enables the reaction intermediate to be easily purified, thus being suitable for the industrialized production of the full protection heparin pentasaccharide.

Abstract: The present invention provides a weir quench, an apparatus comprising a reactor and the weir quench and processes incorporating the same. The weir quench incorporates an inlet having an inner diameter (Di) and an upper chamber having an inner diameter (Duc), wherein the inlet inner diameter (Di) is at least 90% of the upper chamber inner diameter (Duc). The apparatus comprises a reactor having an outlet with an inner diameter fluidly coupled with the weir quench inlet, wherein the ratio of the reactor outlet inner diameter (Dr) to the weir quench inlet diameter (Di) is greater than one. The weir quench, and apparatus comprising a reactor and the weir no quench, are advantageously utilized in processes utilizing a limiting reagent.

Abstract: The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.

Abstract: Provided in the present invention are novel benzodioxole derivatives and preparation methods thereof. These compounds represented by formula (I) or pharmaceutically acceptable salts thereof have acetylcholinesterase inhibitory activity, so can be used in the treatment or prevention of Alzheimer's disease. The definitions of R1, R2 and A of formula (I) can be seen in the description.

Abstract: An apparatus for continuously manufacturing organometallic compounds is provided where the apparatus has a source of a first reactant stream wherein the first reactant comprises a metal; a source of a second reactant stream; a laminar flow contacting zone for cocurrently contacting the first reactant stream and the second reactant stream; a mixing zone comprising a turbulence-promoting device; and a heat transfer zone.

Abstract: The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula I, which is defined in the specification. The compounds according to the present invention can be used as PPAR agonists, and demonstrates a strong effect on reducing the levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in blood plasma, and thus the compound according to the present invention can be used in the preparation of a medicament for treating or preventing hyperlipoidemia or cardio-cerebrovascular diseases caused by hyperlipoidemia, such as diabetes, atherosclerosis, stroke, coronary heart disease, etc. The present invention also relates to a novel intermediate compound for the preparation of the compound of formula I and preparation method thereof.

Abstract: A method of continuously manufacturing organometallic compounds is provided where two or more reactants are conveyed to a reactor having a laminar flow contacting zone, a heat transfer zone, and a mixing zone having a turbulence-promoting device; and causing the reactants to form the organometallic compound.

Abstract: The present invention provides a crystalline form of HPPH (2-((1?-n-hexyloxy)ethyl)-2-divinyl-pyropheophorbide-a). The crystalline form can be characterized by an X-ray powder diffraction (XRD) pattern and differential scanning calorimeter (DSC) pattern. The present invention also provides a method for preparing the crystalline form of HPPH.

Abstract: An antibacterial paper comprises a paper substrate, wherein at least one external surface of the paper substrate is coated with an antibacterial coating layer containing titanium dioxide particles uniformly distributed therein, the average particle size of the titanium dioxide particles is less than or equal to 200 nanometers (nm), and the mass percentage of the titanium dioxide particles contained in the antibacterial coating layer is more than or equal to 5% of the mass of the antibacterial coating layer.

Abstract: A plug side surface of a plug housing is provided with a claw portion. The claw portion includes a plug lock surface facing in a direction away from a connector mounting surface. Each assistant fitting of a receptacle connector includes a receptacle lock surface that faces in a direction approaching the connector mounting surface and is opposed to the plug lock surface in a mated state. The plug lock surface includes a lock maintaining surface and an unlocking surface. Assuming that an angle formed between a reference plane and the lock maintaining surface is a lock maintaining angle and an angle formed between the reference plane and the unlocking surface is an unlocking angle, the lock maintaining angle is smaller than the unlocking angle.

Abstract: The present invention relates generally to the field of food and beverages. In particular, the present invention relates to a powdered beverage comprising fruit or vegetable pulp. Embodiments of the present invention relate to compositions comprising dry fruit or vegetable pulp and sugar powder, wherein the size of the sugar powder particles and pulp particles is selected in a way that, e.g., segregation of low density pulp particles is avoided during transportation and storage time.

Abstract: Provided is a method for preparing 3-O-benzyl-1,2-O-isopropylidene-?-L-idofuranose, which comprises: (1) protecting hydroxyl of 3-O-benzyl-1,2-O-isopropylidene-?-D-glucofuranose (III) by benzoyl and methylsulfonyl to obtain 6-O-benzoyl-3-O-benzyl-1,2-O-isopropylidene-5-O-methylsulfonyl-?-D-glucofuranose (V); (2) subjecting compound (V) to a cyclization reaction under an alkaline condition to obtain 5,6-epoxy-3-O-benzyl-1,2-O-isopropylidene-?-L-idofuranose (VI); and (3) subjecting compound (VI) to a ring-opening reaction to obtain 3-O-benzyl-1,2-O-isopropylidene-?-L-idofuranose.